FY2026 EPS Estimates for Zai Lab Increased by Analyst

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) – Research analysts at Leerink Partnrs lifted their FY2026 EPS estimates for shares of Zai Lab in a report released on Monday, June 30th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings of $0.33 per share for the year, up from their prior forecast of $0.29. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.05. The firm had revenue of $106.49 million for the quarter, compared to the consensus estimate of $118.40 million. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%.

Other equities analysts also recently issued reports about the stock. JPMorgan Chase & Co. boosted their price target on shares of Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, March 13th. Wall Street Zen downgraded shares of Zai Lab from a “buy” rating to a “hold” rating in a report on Friday, June 27th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a report on Thursday, March 27th. Leerink Partners set a $75.00 price target on shares of Zai Lab and gave the stock an “outperform” rating in a report on Monday. Finally, Scotiabank initiated coverage on shares of Zai Lab in a report on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 price target on the stock. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $54.28.

Zai Lab Price Performance

NASDAQ ZLAB opened at $36.43 on Wednesday. The business’s fifty day moving average is $33.71 and its 200-day moving average is $31.32. The stock has a market capitalization of $4.05 billion, a price-to-earnings ratio of -14.63 and a beta of 0.99. Zai Lab has a one year low of $16.01 and a one year high of $44.34.

Institutional Investors Weigh In On Zai Lab

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kingsview Wealth Management LLC raised its stake in Zai Lab by 6.0% in the 1st quarter. Kingsview Wealth Management LLC now owns 9,323 shares of the company’s stock valued at $337,000 after acquiring an additional 529 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Zai Lab during the fourth quarter valued at about $29,000. Pictet Asset Management Holding SA purchased a new stake in shares of Zai Lab in the fourth quarter worth about $31,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Zai Lab by 2.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company’s stock worth $1,496,000 after buying an additional 1,200 shares in the last quarter. Finally, Walleye Capital LLC lifted its holdings in shares of Zai Lab by 6.4% in the first quarter. Walleye Capital LLC now owns 22,276 shares of the company’s stock worth $805,000 after buying an additional 1,338 shares in the last quarter. 41.65% of the stock is currently owned by institutional investors.

Insider Activity at Zai Lab

In related news, Director William Lis sold 13,814 shares of the business’s stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $35.67, for a total value of $492,745.38. Following the sale, the director directly owned 35,106 shares in the company, valued at approximately $1,252,231.02. The trade was a 28.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Ying Du sold 7,072 shares of the business’s stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $35.23, for a total value of $249,146.56. Following the completion of the sale, the chief executive officer owned 536,962 shares in the company, valued at $18,917,171.26. This represents a 1.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 160,155 shares of company stock worth $4,959,535. Company insiders own 4.96% of the company’s stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.